Cargando…

Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment

BACKGROUND: Despite the success of TNF-inhibitor therapy in rheumatoid arthritis treatment, up to 40% of patients fail to respond adequately. This study aimed to identify transcriptome-based biomarkers of adalimumab response in rheumatoid arthritis (RA) to aid timely switching in non-responder patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	OIiver, James, Nair, Nisha, Orozco, Gisela, Smith, Samantha, Hyrich, Kimme L., Morgan, Ann, Isaacs, John, Wilson, Anthony G., Barton, Anne, Plant, Darren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7948368/ https://www.ncbi.nlm.nih.gov/pubmed/33691749 http://dx.doi.org/10.1186/s13075-021-02451-9

Ejemplares similares

Correction to: Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment
por: Oliver, James, et al.
Publicado: (2021)

Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score
por: Gilani, Syed SA, et al.
Publicado: (2020)

Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis
por: Nair, Nisha, et al.
Publicado: (2020)

Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples
por: Smith, Samantha Louise, et al.
Publicado: (2015)

Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis
por: Smith, Samantha Louise, et al.
Publicado: (2023)

Profiling of Gene Expression Biomarkers as a Classifier of Methotrexate Nonresponse in Patients With Rheumatoid Arthritis
por: Plant, Darren, et al.
Publicado: (2019)

Pre-defined gene co-expression modules in rheumatoid arthritis transition towards molecular health following anti-TNF therapy
por: Sutcliffe, Megan, et al.
Publicado: (2022)

Previously reported PDE3A–SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort
por: Smith, Samantha Louise, et al.
Publicado: (2016)

Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis
por: Plant, Darren, et al.
Publicado: (2016)

Genome-Wide Association Study of Genetic Predictors of Anti–Tumor Necrosis Factor Treatment Efficacy in Rheumatoid Arthritis Identifies Associations with Polymorphisms at Seven Loci
por: Plant, Darren, et al.
Publicado: (2011)

Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis
por: Hum, Ryan M, et al.
Publicado: (2022)

The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort
por: Smith, Samantha Louise, et al.
Publicado: (2017)

Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis
por: Massey, Jonathan, et al.
Publicado: (2018)

Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics
por: Maciejewski, Mateusz, et al.
Publicado: (2021)

Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels
por: Jani, Meghna, et al.
Publicado: (2016)

High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort
por: Jani, Meghna, et al.
Publicado: (2017)

Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort
por: Plant, Darren, et al.
Publicado: (2012)

Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort
por: Bluett, James, et al.
Publicado: (2015)

Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort
por: Bluett, J, et al.
Publicado: (2014)

Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity
por: Hyrich, Kimme L., et al.
Publicado: (2009)

Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?
por: Jani, Meghna, et al.
Publicado: (2019)

Replication of Association of the PTPRC Gene With Response to Anti–Tumor Necrosis Factor Therapy in a Large UK Cohort
por: Plant, Darren, et al.
Publicado: (2012)

Demyelinating Events Following Initiation of Anti-TNFα Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis
por: Taylor, Thomas R.P., et al.
Publicado: (2021)

Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register
por: Soliman, Moetaza M, et al.
Publicado: (2011)

Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2018)

Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment
por: Tan, Rachael J L, et al.
Publicado: (2010)

What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?
por: Humphreys, Jenny, et al.
Publicado: (2016)

Long-term outcomes of patients who rate symptoms of rheumatoid arthritis as ‘satisfactory’
por: Gwinnutt, James M, et al.
Publicado: (2020)

The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis
por: Silva-Fernández, Lucía, et al.
Publicado: (2016)

Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti‑TNF therapy: results from the British Society for Rheumatology Biologics Register
por: Davies, Rebecca, et al.
Publicado: (2011)

Impact of Psychological Factors on Subjective Disease Activity Assessments in Patients With Severe Rheumatoid Arthritis
por: Cordingley, Lis, et al.
Publicado: (2014)

Proteomic analysis to define predictors of treatment response to adalimumab or methotrexate in rheumatoid arthritis patients
por: Ling, Stephanie F., et al.
Publicado: (2019)

Changes in the illness perceptions of patients with rheumatoid arthritis over the first year of methotrexate therapy
por: Gwinnutt, James M, et al.
Publicado: (2020)

Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis
por: Potter, C, et al.
Publicado: (2009)

Do people with rheumatoid arthritis maintain their physical activity level at treatment onset over the first year of methotrexate therapy?
por: Gwinnutt, James M, et al.
Publicado: (2021)

Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39
por: Spiliopoulou, Athina, et al.
Publicado: (2019)

Predictors of presenteeism, absenteeism and job loss in patients commencing methotrexate or biologic therapy for rheumatoid arthritis
por: Gwinnutt, James M, et al.
Publicado: (2020)

Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register
por: Saad, Amr A., et al.
Publicado: (2010)

Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register
por: Saad, Amr A., et al.
Publicado: (2017)

Effectiveness and safety of TNF inhibitors in adults with juvenile idiopathic arthritis
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_n1bu3lkau8q2iluuehpl5m7ufd